Brokerages Set Novavax, Inc. (NVAX) Price Target at $39.29

Shares of Novavax, Inc. (NASDAQ:NVAX) have been given an average recommendation of “Hold” by the twelve research firms that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $39.29.

A number of research analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $120.00 price objective on shares of Novavax in a report on Thursday, February 28th. B. Riley dropped their price objective on shares of Novavax from $200.00 to $35.00 and set a “buy” rating for the company in a report on Monday, March 4th. Zacks Investment Research upgraded shares of Novavax from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Friday, March 22nd. Cantor Fitzgerald set a $20.00 price objective on shares of Novavax and gave the company a “hold” rating in a report on Tuesday, March 19th. Finally, ValuEngine upgraded shares of Novavax from a “buy” rating to a “strong-buy” rating in a report on Friday, May 10th.

Shares of NVAX opened at $5.90 on Tuesday. The stock has a market cap of $138.47 million, a price-to-earnings ratio of -0.59 and a beta of 2.31. Novavax has a 1-year low of $5.45 and a 1-year high of $51.60.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.40) by $0.20. The business had revenue of $3.98 million during the quarter, compared to analyst estimates of $4.80 million. During the same quarter last year, the firm posted ($2.80) EPS. Equities research analysts anticipate that Novavax will post -6.93 EPS for the current year.

In other news, Director Rachel K. King purchased 86,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was bought at an average price of $0.53 per share, for a total transaction of $45,580.00. Following the completion of the purchase, the director now directly owns 42,000 shares of the company’s stock, valued at $22,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.30% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of NVAX. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Novavax by 131.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,729 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 9,515 shares during the last quarter. Opti Capital Management LP purchased a new stake in shares of Novavax during the 4th quarter worth approximately $39,000. Toroso Investments LLC purchased a new stake in shares of Novavax during the 4th quarter worth approximately $82,000. DAVENPORT & Co LLC lifted its position in shares of Novavax by 400.0% during the 1st quarter. DAVENPORT & Co LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 40,000 shares during the last quarter. Finally, Amalgamated Bank lifted its position in shares of Novavax by 32.0% during the 4th quarter. Amalgamated Bank now owns 54,361 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 13,171 shares during the last quarter.

Novavax Company Profile

Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.

Featured Story: Investing in Growth Stocks

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.